137 related articles for article (PubMed ID: 7385100)
1. Antithrombotic effects of ticlopidine, acetylsalicyclic acid and dipyridamole in vascular shunt model in rats.
Ashida S; Sakuma K; Abiko Y
Thromb Res; 1980 Mar; 17(5):663-71. PubMed ID: 7385100
[No Abstract] [Full Text] [Related]
2. Modulation of the inhibitory action of prostaglandin E1 on platelet aggregation in rats: a study with ticlopidine, aspirin, dipyridamole and sulfinpyrazone.
Tuong CC; Ferrand C; Aubert D; Loubrie JC; Tuong A
Biochem Pharmacol; 1982 Mar; 31(6):1147-50. PubMed ID: 7200772
[No Abstract] [Full Text] [Related]
3. Effects of ticlopidine on thrombotic obstruction of A-V shunts and on dialysance of artificial kidneys.
Maeda K; Usuda M; Kawaguchi S; Shinzato T; Saito A; Ohta K; Kobayashi K; Ohbayashi S; Narita M
Artif Organs; 1980 Feb; 4(1):30-3. PubMed ID: 7369892
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of ticlopidine on experimentally induced peripheral arterial occlusive disease in rats.
Ashida S; Ishihara M; Ogawa H; Abiko Y
Thromb Res; 1980 Apr 1-15; 18(1-2):55-67. PubMed ID: 7404505
[No Abstract] [Full Text] [Related]
5. Ticlopidine as an experimental antithrombotic agent.
Vallée E; Maffrand JP; Bernat A; Delebassée D; Tissinier A
Agents Actions Suppl; 1984; 15():50-9. PubMed ID: 6592945
[No Abstract] [Full Text] [Related]
6. Antiplatelet aggregators inhibit development of stress ulcers in Sprague-Dawley rats.
Kumashiro R; Piotrowski JJ; Kholoussy AM; Hashimoto N; Matsumoto T
Eur Surg Res; 1985; 17(1):44-52. PubMed ID: 3972005
[TBL] [Abstract][Full Text] [Related]
7. Experimental model of venous thrombosis in rats and effect of some agents.
Kumada T; Ishihara M; Ogawa H; Abiko Y
Thromb Res; 1980 Apr 1-15; 18(1-2):189-203. PubMed ID: 7404498
[No Abstract] [Full Text] [Related]
8. Antithrombotic effect of ticlopidine in a platelet-independent model of venous thrombosis.
Bernat A; Vallée E; Maffrand JP; Roncucci R
Thromb Res; 1985 Jan; 37(2):279-85. PubMed ID: 3975872
[TBL] [Abstract][Full Text] [Related]
9. [Kinetics of I-131 fibrinogen in cancer patients: pharmacological approach].
Boneu-Valmalette A; Bugat R; David JF; Combes PF
C R Seances Soc Biol Fil; 1977; 171(6):1293-6. PubMed ID: 148961
[TBL] [Abstract][Full Text] [Related]
10. The interactions of ticlopidine and aspirin in normal subjects.
Thebault JJ; Blatrix CE; Blanchard JF; Panak EA
J Int Med Res; 1977; 5(6):405-11. PubMed ID: 590598
[TBL] [Abstract][Full Text] [Related]
11. [Platelet antiaggregants and bleeding time lengthening: management in the preoperative period].
Thébault JJ; Blatrix C; Blanchard J; Panak E
Agressologie; 1983 Dec; 24(12):609-11. PubMed ID: 6670692
[No Abstract] [Full Text] [Related]
12. Platelet aggregation measured in rabbit whole blood: in vitro study of 3 aggregating agents and ex vivo inhibition by aspirin and ticlopidine.
Chevolet C; Grosdent JC; Reiters GM; Dresse A
Arch Int Pharmacodyn Ther; 1982 Oct; 259(2):310-1. PubMed ID: 6817725
[No Abstract] [Full Text] [Related]
13. Antithrombotic activity of F 16618, a new PAR1 antagonist evaluated in extracorporeal arterio-venous shunt in the rat.
Létienne R; Leparq-Panissié A; Calmettes Y; Nadal-Wollbold F; Perez M; Le Grand B
Biochem Pharmacol; 2010 Jun; 79(11):1616-21. PubMed ID: 20188709
[TBL] [Abstract][Full Text] [Related]
14. The antiaggregating and antithrombotic activity of ticlopidine is potentiated by aspirin in the rat.
Herbert JM; Bernat A; Samama M; Maffrand JP
Thromb Haemost; 1996 Jul; 76(1):94-8. PubMed ID: 8819259
[TBL] [Abstract][Full Text] [Related]
15. Effect of the antiplatelet agents ticlopidine and dipyridamole on experimental immune complex glomerulonephritis in rats.
Izumino K; Iida H; Asaka M; Mizumura Y; Sasayama S
Nephron; 1986; 43(1):56-61. PubMed ID: 2939358
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo and in vivo evaluation of drugs that inhibit platelet function.
Hanson SR; Harker LA
Ann N Y Acad Sci; 1983; 416():642-50. PubMed ID: 6587821
[No Abstract] [Full Text] [Related]
17. Effects of various antiplatelet drugs and defibrinating agent on experimental glomerulonephritis in rats.
Ogawa S; Naruse T
J Lab Clin Med; 1982 Mar; 99(3):428-41. PubMed ID: 6460069
[TBL] [Abstract][Full Text] [Related]
18. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin.
Moncada S; Korbut R
Lancet; 1978 Jun; 1(8077):1286-9. PubMed ID: 78050
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban.
Kawamura M; Imura Y; Moriya N; Kita S; Fukushi H; Sugihara H; Nishikawa K; Terashita Z
J Pharmacol Exp Ther; 1996 Apr; 277(1):502-10. PubMed ID: 8613960
[TBL] [Abstract][Full Text] [Related]
20. Suloctidil: a novel inhibitor of platelet aggregation in human beings.
de Gaetano G; Miragliotta G; Roncucci R; Lansen J; Lambelin G
Thromb Res; 1976 Mar; 8(3):361-71. PubMed ID: 1265708
[No Abstract] [Full Text] [Related]
[Next] [New Search]
